

6643R2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: James B. Camden, et al.      §  
Serial No.: 09/676,034      §  
Filed: September 29, 2000      §  
For: Compounds and Methods for Use      §  
      Thereof In the Treatment of Cancer      §  
      or Viral Infections      §

Examiner: Delacroix Muirheid, C.  
Group Art Unit: 1614  
Customer No.: 30113

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**RESPONSE TO OFFICE ACTION**  
**MAILED AUGUST 19, 2002**

The present paper is submitted as a complete response to the Official Action mailed August 19, 2002 having a shortened statutory period of response of three months, to November 19, 2002. The present paper is timely filed since this paper is being filed prior to or on the three-month date; however, should an extension of time be required, this paper is such a request. No fees are believed due for the filing of the present document, however, should any fees be due, the Commissioner is authorized to deduct said fees under 37 C.F.R. §§ 1.16 to 1.21 from Haynes and Boone Deposit Account No. 08-1394.

**REMARKS****I. Status of the Claims**

Claims 1-4, 6-12, 14-20, 23, and 24 are pending in the application.

**II. Information Disclosure Statement**

Applicant requests that the examiner make a statement of record that the pending applications of pages 4-8 of the Information Disclosure Statement of October 30, 2000 are made of record even though they are crossed through on the copy returned with the present action.

**III. Rejection of Claims for Obviousness-Type Double Patenting**

Claims were rejected for obviousness-type double patenting over claims of the following patents:  
U.S. 6,423,736,

#9  
JLP  
11/14/02